Cognition Therapeutics (CGTX) was notified by Nasdaq that the company has regained compliance with the exchange’s continued listing standard for minimum share price under Rule 5550.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics Reports Q2 2025 Financial Results
- Cognition Therapeutics confirms aligment with FDA on path for zervimesine
- Promising Developments and Regulatory Milestones Drive Buy Rating for Cognition Therapeutics
- Cognition Therapeutics reports Q2 EPS (11c), consensus (10c)
- Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors